Florida Cancer Specialists & Research Institute, LLC (FCS) advances genitourinary cancer treatment through participation at ...

Dana-Farber Cancer Institute presents phase 3 LITESPARK-022 data at the 2026 ASCO Genitourinary Cancers SymposiumPatients ...

Gemcitabine intravesical system+intravenous cetrelimab did not improve bladder-intact event-free survival or OS for pts with MIBC who did not receive radical cystectomy.

The new drug uses a so-called cloaking device and only activates when it reaches the tumour ...

At the 2026 ASCO Genitourinary Cancers Symposium, Dr. Andrea Necchi shared the final results of the SunRISe-2 phase 3 trial, ...

Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...

EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb.

Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, presents findings from the phase 3 LITESPARK-022 study at the 2026 American Society of ...

A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, with patients who had previously stopped being receptive to treatment finding their tumours shrinking, ...

New Delhi [India], February 25: Indraprastha Apollo Hospitals has launched the Varian Edge Radiosurgery System with Hyperarc Technology, strengthening its advanced cancer care capabilities and ...

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3 Data highlight the potential of this first-in-class next-generation ...